Anticancer drug screening and discovery in the 1990s: a European perspective

European Journal of Cancer

Volumn 29, Issue 1, 1993, Pages 3-14

  Schwartsmann, G ^a   Workman, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; DRUG SCREENING; EUROPE; PRIORITY JOURNAL; REVIEW;

ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; EUROPE; HUMAN; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS, EXPERIMENTAL; ONCOGENES; RESEARCH; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0027420205     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(93)90567-Y     Document Type: Note

References (126)

1. Clinical drug development: An analysis of phase II trials, 1970–1985
2. Is the P388 murine tumour no longer adequate as a drug discovery model?
3. In Defense of Cell-Line Screening
4. Current Status of cancer drug development: Failure or limited success?
5. Unwarranted pessimism in cancer chemotherapy
6. Screening methods in antineoplastic drug discovery
7. Anticancer drug discovery
8. Drug evaluation in experimental tumour systems: Potential and limitations in 1961
9. Experimental screening procedures and clinical predictability value
10. Historical development and current strategy of the National Cancer Drug Development Program
11. Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute
12. The drug development and clinical trials programs of the Division of Cancer Treatment, National Cancer Institute
13. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
14. The main steps in the development of anticancer agents
15. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetraolium assay
16. Status of the NCI Preclinical Anticancer Drug Discovery Screen
17. Some marine ecological phenomena: Chemical basis and biomedical potential
18. The search for molecular diversity
19. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
20. Display and analysis of patterns of differential activity of drugs against human tumour cell lines: Development of mean graph and COMPARE algorithm
21. Antineoplastic drug screening belongs in the laboratory, not in the clinic
22. Anthrapyrazoles: True successors to the anthracyclines?
23. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes
24. A novel investigational new drug for lung cancer
25. The role of NAD(P)H: Quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9
26. DT-diaphorase and cancer chemotherapy
27. Flavone Acetic Acid: Is Vascular Shutdown the Crucial Mechanism of Action
28. Mechanism-based discovery of anticancer agents
29. Primary bioassay of human tumor stem cells
30. Application of a human tumor colony-forming assay to new drug screening
31. He's not going to talk about in vitro predictive assays again, is he?
32. New approaches to antitumour drug screening: The human tumor colony-forming assay
33. Completion of the dihydrolenperone Phase I trial, a novel compound with in vitro activity against lung cancer
34. Chloroquinoxaline sulfonamide: A Phase I study of a unique agent with preclinical and clinical activity in non-small cell lung cancer
35. A critical appraisal of the predictive value of in vitro chemosensitivity assays
36. Effects of suramin on in vitro growth of fresh human tumors
37. Clinical productivity of transplantable tumor systems in the selection of new drugs for solid tumors: Rationale for a three-stage strategy
38. Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents
39. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo
40. Proposal for application of xenografts in screening for new anticancer agents and in selecting tumor types for phase II clinical trials
41. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development
42. New anticancer drug development: Results of a five-year cooperative program between the EORTC-NDDO and the Freiburg preclinical anticancer drug development group
43. Phase I and pharmacokinetic study of rhizoxin
44. Phase I study of taxotere (RP 56976) administered as a 24 hour infusion
45. Therapeutic index: A vital component in selection of anticancer agents for clinical trial
46. Selectivity and potency; Are we doing the right things to find anti-cancer agents with these properties?
47. Experimental antitumour activity against murine model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad spectrum agent
48. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine
49. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
50. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating, carcinogenic and therapeutic agents
51. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas
52. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumour effect of flavone-8-acetic acid and analogs in mice
53. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug resistant cell lines, and further resistance modification by verapamil and cyclosporin A
54. 9-Alkyl morpholinyl anthracyclines in multidrug resistance
55. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression
56. In vivo antitumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells
57. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: A cautionary note
58. Has chemotherapy anywhere to go?
59. Analogues of aminoglutethimide. Selective inhibition of aromatase
60. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor,4-hydroxyandrostenedione: Phase II report
61. Oncogenes and signal transduction
62. Growth factors and cancer
63. Tumor suppressor genes
64. Signalling targets for anticancer drug development
65. The cell membrane and cell signals as targets in cancer chemotherapy
66. The cell membrane and cell signals: new targets for novel anticancer drugs
67. Suramin: An anticancer drug with a unique mechanism of action
68. The molecular genetics of cancer
69. A thousand and one protein kinases
70. Molecular analysis of signal transduction by growth factors
71. Complexities of the protein kinase C pathway
72. Tyrphostins as molecular tools and potential antiproliferative drugs
73. cdc2 protein kinase
74. Tyrosine kinases as a target for chemotherapy
75. Potent and specific inhibitors of protein kinase C of microbial origin
76. Isolation and structure of bryostatin 1
77. A Phase I study of bryostatin 1 — a protein kinase C partial agonist
78. Antitumour ether lipids. Membrane-interactive lipids as experimental anticancer drugs
79. Selective inhibition of isoprenylation of 21–26KDa proteins by the anticarcinogen d-limonene and its metabolites
80. Signal transduction through small GTPases—a tale of two GAPs
81. A transcription factor (?) joins the SH2 crowd
82. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
83. DNA as a target for drug action
84. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065
85. Reaction of the antitumour antibiotic CC-1065 with DNA: Structure of DNA adduct with DNA sequence specificity
86. Selective DNA interaction of the novel distamycin derivative FCE 24517
87. Designed enediynes: A new class of DNA-cleaving molecules with potent and selective anticancer activity
88. Drug-target interactions: only the first step in the commitment to a programmed cell death?
89. How to kill cancer cells: Membranes and cell signaling as targets in cancer chemotherapy
90. p53, Guardian of the genome
91. Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity
92. Bioreductive mechanisms
93. SR 4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
94. Synthesis and evaluation of .alpha.-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of .alpha.-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogs which are radiosensitizers and bioreductively activated cytotoxins
95. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
96. Enzyme-directed bioreductive drug development
97. DNA topoisomerase poisons as antitumour drugs
98. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice
99. Preclinical studies of a new topoisomerase I inhibitor
100. DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts
101. Antimitotic natural products combrestatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin
102. Dolastatin 10: A potent new antimitotic agent isolated from a marine animal which binds in the vinblastine domain of tubulin
103. Taxol: An antimitotic agent with a new mechanism of action
104. Experimental properties of RP 56976, a taxol derivative
105. Rhizoxin binding to tubulin at the maytansine-binding site
106. New drug development
107. Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein in GTP hydrolysis
108. Protein structure determination in solution by nuclear magnetic resonance spectroscopy
109. Prediction of protein structure from sequence
110. Genetic engineering and pharmaceuticals
111. The impact of biotechnology on drug discovery
112. Searching for peptide ligands with an epitope library
113. A new type of synthetic peptide library for identifying ligand-binding activity
114. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery
115. Antibody-directed drug discovery
116. Antibody-directed enzyme prodrug therapy
117. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental rat brain tumors
118. Biology approaches the teraflop era
119. Design of enzyme inhibitors using iterative protein crystallographic analysis
120. In vitro properties and antitumour activity of AG-331, a novel lipophilic thymidylate synthase inhibitor
121. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
122. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
123. Fishing in src-infested waters